» Articles » PMID: 37405658

Generation of Human 293-F Suspension NGFR Knockout Cells Using CRISPR/Cas9 Coupled to Fluorescent Protein Expression

Overview
Specialty Molecular Biology
Date 2023 Jul 5
PMID 37405658
Authors
Affiliations
Soon will be listed here.
Abstract

Suspension cells derived from human embryonic kidney cells (HEK 293) are attractive cell lines for retroviral vector production in gene therapeutic development studies and applications. The low-affinity nerve growth factor receptor (NGFR) is a genetic marker frequently used as a reporter gene in transfer vectors to detect and enrich genetically modified cells. However, the HEK 293 cell line and its derivatives endogenously express the NGFR protein. To eradicate the high background NGFR expression in future retroviral vector packaging cells, we here employed the CRISPR/Cas9 system to generate human suspension 293-F NGFR knockout cells. The expression of a fluorescent protein coupled via a 2A peptide motif to the NGFR targeting Cas9 endonuclease enabled the simultaneous depletion of cells expressing Cas9 and remaining NGFR-positive cells. Thus, a pure population of NGFR-negative 293-F cells lacking persistent Cas9 expression was obtained in a simple and easily applicable procedure.

Citing Articles

Generation of Antibodies Selectively Recognizing Epitopes in a Formaldehyde-Fixed Cell-Surface Antigen Using Virus-like Particle Display and Hybridoma Technology.

Schatz S, Willnow L, Winkels M, Rosengarten J, Theek B, Johnston I Antibodies (Basel). 2023; 12(3).

PMID: 37753971 PMC: 10525569. DOI: 10.3390/antib12030057.

References
1.
Walsh G . Biopharmaceutical benchmarks 2018. Nat Biotechnol. 2018; 36(12):1136-1145. DOI: 10.1038/nbt.4305. View

2.
Dumont J, Euwart D, Mei B, Estes S, Kshirsagar R . Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives. Crit Rev Biotechnol. 2015; 36(6):1110-1122. PMC: 5152558. DOI: 10.3109/07388551.2015.1084266. View

3.
Peters R, Toby G, Lu Q, Liu T, Kulman J, Low S . Biochemical and functional characterization of a recombinant monomeric factor VIII-Fc fusion protein. J Thromb Haemost. 2012; 11(1):132-41. PMC: 3588154. DOI: 10.1111/jth.12076. View

4.
McCue J, Osborne D, Dumont J, Peters R, Mei B, Pierce G . Validation of the manufacturing process used to produce long-acting recombinant factor IX Fc fusion protein. Haemophilia. 2014; 20(4):e327-35. PMC: 4282370. DOI: 10.1111/hae.12451. View

5.
Fontana D, Garay E, Cervera L, Kratje R, Prieto C, Godia F . Chimeric VLPs Based on HIV-1 Gag and a Fusion Rabies Glycoprotein Induce Specific Antibodies against Rabies and Foot-and-Mouth Disease Virus. Vaccines (Basel). 2021; 9(3). PMC: 7999769. DOI: 10.3390/vaccines9030251. View